Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

BackgroundParenteral anti-CD3 Mab (OKT3) has been used to treat transplant rejection and parental administration of a humanized anti-CD3 Mab (Teplizumab) showed positive effects in diabetes. Nasal administration of anti-CD3 Mab has not been carried out in humans. Nasal anti-CD3 Mab suppresses autoim...

Full description

Bibliographic Details
Main Authors: Tanuja Chitnis, Belinda J. Kaskow, Junning Case, Katherine Hanus, Zhenhua Li, Johnna F. Varghese, Brian C. Healy, Christian Gauthier, Taylor J. Saraceno, Shrishti Saxena, Hrishikesh Lokhande, Thais G. Moreira, Jonathan Zurawski, Rachel E. Roditi, Regan W. Bergmark, Federico Giovannoni, Maria F. Torti, Zhaorong Li, Francisco Quintana, William A. Clementi, Kunwar Shailubhai, Howard L. Weiner, Clare M. Baecher-Allan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
Foralumab
nasal anti-CD3
immunomodulation
CD8+ T cells
Tregs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.956907/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.956907/full

Similar Items